Sangamo Therapeutics, Inc. (SGMO) VP Sells $225,000.00 in Stock
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) VP Curt A. Herberts III sold 15,000 shares of the company’s stock in a transaction on Friday, September 1st. The shares were sold at an average price of $15.00, for a total transaction of $225,000.00. Following the completion of the sale, the vice president now directly owns 15,833 shares in the company, valued at $237,495. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) opened at 14.25 on Monday. The firm’s 50-day moving average is $10.04 and its 200 day moving average is $7.00. The firm’s market cap is $1.19 billion. Sangamo Therapeutics, Inc. has a 12-month low of $2.65 and a 12-month high of $15.05.
Sangamo Therapeutics (NASDAQ:SGMO) last announced its earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.17) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.06. Sangamo Therapeutics had a negative net margin of 246.39% and a negative return on equity of 38.49%. The firm had revenue of $8.30 million for the quarter, compared to analysts’ expectations of $5.82 million. During the same quarter in the previous year, the business posted ($0.38) EPS. The company’s quarterly revenue was up 124.3% on a year-over-year basis. Equities analysts forecast that Sangamo Therapeutics, Inc. will post ($0.82) earnings per share for the current year.
ILLEGAL ACTIVITY WARNING: “Sangamo Therapeutics, Inc. (SGMO) VP Sells $225,000.00 in Stock” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/sangamo-therapeutics-inc-sgmo-vp-sells-225000-00-in-stock/1541021.html.
Hedge funds have recently made changes to their positions in the company. Blair William & Co. IL boosted its holdings in shares of Sangamo Therapeutics by 4.3% during the 2nd quarter. Blair William & Co. IL now owns 12,100 shares of the biopharmaceutical company’s stock valued at $106,000 after buying an additional 500 shares in the last quarter. Aperio Group LLC bought a new stake in shares of Sangamo Therapeutics during the 2nd quarter valued at $108,000. Principal Financial Group Inc. boosted its holdings in shares of Sangamo Therapeutics by 6.8% during the 2nd quarter. Principal Financial Group Inc. now owns 12,978 shares of the biopharmaceutical company’s stock valued at $114,000 after buying an additional 832 shares in the last quarter. Virtu KCG Holdings LLC bought a new stake in shares of Sangamo Therapeutics during the 2nd quarter valued at $124,000. Finally, Fox Run Management L.L.C. bought a new stake in shares of Sangamo Therapeutics during the 2nd quarter valued at $126,000. Hedge funds and other institutional investors own 63.43% of the company’s stock.
Several research analysts recently issued reports on SGMO shares. Jefferies Group LLC reissued a “buy” rating and set a $17.00 target price on shares of Sangamo Therapeutics in a research note on Thursday, June 22nd. Zacks Investment Research raised shares of Sangamo Therapeutics from a “hold” rating to a “buy” rating and set a $12.00 target price on the stock in a research note on Friday, August 18th. BidaskClub lowered shares of Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, July 28th. ValuEngine raised shares of Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 11th. Finally, Piper Jaffray Companies set a $8.00 target price on shares of Sangamo Therapeutics and gave the stock a “hold” rating in a research note on Thursday, August 10th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $10.25.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc, formerly Sangamo BioSciences, Inc, is a clinical-stage biotechnology company. The Company is focused on translating science into genomic therapies that transform patients’ lives using the Company’s platform technologies in genome editing, gene therapy, gene regulation and cell therapy.
Receive News & Ratings for Sangamo Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.